News and Events

This article from Charles River Laboratories dives into how NGS is transforming adventitious virus testing, offering greater sensitivity and comprehensive detection compared to traditional methods. As NGS continues to play a pivotal role in biosafety, this insight...

JOINT WEBINAR Takeda, PathoQuest & Charles River Laboratories   Adventitious Agent Testing For MMV: How Much Do We Really Know?   01st October 2024 10:00am EDT / 7:00am PDT / 3:00pm BST / 4:00pm CEST Presented by: Maria Farcet, Head of Cell Culture, Virus...

We are delighted to welcome Stanley Prince as Chief Commercial Officer at PathoQuest! With 20 years of experience in vaccines, biologics and cell/gene therapies, Stanley Prince’s expertise in GMP services and Next Generation Sequencing (NGS) biotesting will be instrumental in PathoQuest’s growth.

The EFPIA (European Federation of Pharmaceutical Industries and Associations) has released a pivotal position paper on the use of Next Generation Sequencing (NGS) for adventitious virus detection in biological medicinal products.

Pathoquest is thrilled to contribute to the transformative shift in biologics testing, as highlighted in the insightful article by Labiotech.eu. The move towards faster, safer and non-animal based assay is not just a trend; it's the future of ensuring safety and...

Cell Bank Viral Safety: Replace animal-based assays used foradventitious virus and MAP/HAP/RAP (Mouse,Hamster andRat Antibody Production Tests)with one single NGS assay!  Discover how iDTECT® Transcriptome assay transformscell banking & cell therapies products...

Replacing Mouse, Rat and Hamster Antibody Production Tests (MAP/RAP/HAP) with NGS iDTECT®  Transcriptome assay.  Further PathoQuest data to support the switch to iDTECT® NGS for faster, safer, animal free release of cell banks is now available !  The ICH...

JOINT WEBINAR Bristol Myers Squibb & PathoQuest  Applications of Next Generation Sequencing for Viral Safety in Light of ICH Q5A R2 08th February 2024 10:00am EST / 7:00am PST / 3:00pm GMT / 4:00pm CET Presented by: Jurgen Mullberg, Ph.D., Associate Director at...

The updated ICHQ5A(R2) guideline adopted in November 2023 highlights the benefits of Next Generation Sequencing assays versus in vivo assays: 3.2.3: "NGS is encouraged as a replacement for in vivo assays because it can overcome the limitations of the breadth and...

Listen to an archived version of our recent webinar which provided information on our new integration site analysis assay. The assay uses Cas9 targeted DNA cleavage combined with nanopore sequencing technology to comprehensively sequence the junction site. This assay...

Substitution of in vitro and in vivo virus testing with PathoQuest NGS confirmed by French AgencyPathoQuest is pleased to announce that the Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) have recently published their review of PathoQuest’s...

PathoQuest now offering GMP validated NGS Viral Vector Identity test at U.S. siteWe now offer our GMP validated Viral Vector Identity test at our Wayne, PA site, as well as at our site in Paris, France. Our NGS-based identity test is performed on a short read...

PathoQuest’s Chief Pharmaceutical Officer, Sébastien Renouf, PharmD contributes featured blog post on the ICH Q5A(R2) on Eureka science blogA new post on Charles River’s Eureka science blog feature’s PathoQuest’s Chief Pharmaceutical Officer, Sébastien Renouf, PharmD,...

Jean-Francois Brepson interviewed for Amazon Web Services (AWS) Health Innovation Podcast Discover how PathoQuest enables new biotherapies to be delivered rapidly and safely to patients with its quality testing platform in this episode of the AWS Health Innovation...